U.S. CONTINUATION PRACTICE IN LIFE SCIENCES: DESIGNING PATENT FAMILIES, NOT JUST FILLING THEM

In life sciences, patent prosecution is often treated as a checklist exercise: file the application, respond to office actions, obtain allowance, and move on. That transactional mindset may secure a patent. It does not necessarily secure long-term value. 

 The more sophisticated approach is architectural. Instead of asking how to get a patent allowed, the better question is how to design a patent family that preserves flexibility across development, licensing, and commercialization. In a sector where clinical timelines routinely outlast early patent filings, continuation strategy becomes central to patent portfolio risk mitigation. 

Transactional Filing vs. Architectural Design 

Under a transactional model, a company files, prosecutes, and allows a case to mature. Once granted, flexibility is largely gone. 

 Under an architectural model, at least one U.S. case remains pending intentionally. That pendency acts as a strategic reserve. As clinical data evolves, commercial positioning shifts, or regulatory pathways change, claims can be refined through continuation practice. 

• This is particularly important in life sciences, where: 

• Indications expand or narrow during development 

• Responder subgroups emerge from clinical data 

• Label language changes late in the regulatory process 

• Licensing and partnership structures evolve  

If all claims are fixed too early, the ability to tailor protection to real-world developments may be lost. For universities, that can reduce licensing leverage. For biotech companies, it can limit the ability to protect value-creating data. 

Claim Sequencing Is Not Random 

Continuation strategy starts before prosecution begins. The initial claim set should be designed with restriction practice in mind. Composition, method of use, and method of making claims are not merely technical variations. They are strategic layers. 

 In life sciences, composition claims often anchor value. Method of use claims, particularly where regulatory frameworks such as the Orange Book or biologics pathways apply, can reinforce exclusivity. Method of making claims contribute to a picket-fence strategy that complicates competitive entry. 

Structural Discipline Prevents Term Collapse 

Structural discipline matters. Divisional applications benefit from safe harbor against obviousness-type double patenting if consonance is maintained. True continuations do not.  

Without careful planning, terminal disclaimers can collapse patent term across related patents, unintentionally synchronizing expiration dates and reducing effective exclusivity.Strategic patent prosecution must account for these risks from the outset. 

Patent Term Economics Is a Design Variable

Patent term in the United States is not simply a statutory calculation. It is influenced by patent term adjustment, applicant delay, terminal disclaimers, and, uniquely in life sciences, patent term extension tied to FDA approval. 

 Continuation strategy should consider: 

•  Whether patent term adjustment is being eroded by prosecution choices 

• Whether obviousness-type double patenting risks will force terminal disclaimers 

• Which patent is the optimal bearer of patent term extension 

• How patent term aligns with regulatory exclusivity such as new chemical entity, biologic, or orphan drug protection 

 Exclusivity modeling should occur early in development, not at the moment of FDA approval. Intellectual property and regulatory strategy must be integrated, not siloed. 

Layering Families Across the Development Timeline 

In life sciences, the product evolves in phases. Broad foundational claims may be appropriate in preclinical stages. Species, regimen, biomarker, and label-aligned claims often emerge during clinical development. Post-approval, maintaining a live case allows adaptation to commercial realities. 

This layered approach can extend effective exclusivity well beyond what a single early filing would achieve. The goal is not to extend statutory term improperly. It is to deploy patent families deliberately across the life cycle so that protection aligns with development milestones. 

For platform biotech companies, this may mean starting with genus-level coverage and refining toward commercially relevant species as data matures. For universities, maintaining a pending continuation can preserve negotiation flexibility when an ideal licensee emerges years after the first patent issues. 

Continuation Practice as Strategic Infrastructure 

U.S. continuation practice is not merely procedural. It is a core tool in intellectual property strategy for life sciences companies that want to align patent prosecution with commercialization timelines.  

When used intentionally, continuation strategy: 

• Preserves flexibility across development phases 

• Supports licensing leverage 

• Enhances patent portfolio management 

• Reduces structural risks that erode term 

• Strengthens long-term exclusivity planning 

At Hylton-Rodic Law, we work with life sciences innovators to design patent family architecture that aligns with regulatory milestones, valuation strategy, and commercialization pathways. Our team integrates patent prosecution, validity opinions, and patent portfolio risk mitigation into a cohesive framework tailored to biotech and pharmaceutical development. Learn more about our approach to life sciences intellectual property here.  

If your organization is approaching critical development or licensing milestones, now is the time to evaluate whether your U.S. continuation practice is transactional or architectural. A structured review of your pending families can clarify where flexibility is preserved and where it has already narrowed. Connect with our team to discuss your patent portfolio strategy.